← Human Trials & Peer-Reviewed Studies
Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial.
Plain-language guide to PMID 38309436 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 38309436
- Journal
- Journal of substance use and addiction treatment
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Moshiri M et al. (7 authors)
- DOI
- 10.1016/j.josat.2024.209307
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
The researchers conducted a double-blind, randomized clinical trial to assess the effect of magnesium sulfate (MGSO4) as an NMDA receptor antagonist on OWS.
Why It Was Studied
Reactivation of inhibited N-methyl-d-aspartate (NMDA) receptor in person with prolonged opioid use can led to severe OWS.
Who Took Part
PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.
The study randomly divided forty patients with precipitated OWS due to partial agonist (buprenorphine) use referred to the emergency unit of Toxicology Department of Mashhad University of Medical Sciences, Iran; into two groups.
The clinical opiate withdrawal scale (COWS) evaluated OWS at the start of the treatment, 30 min, and 2 h later.
How the Study Was Run
In design terms this was a randomized and double-blind study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
What Was Measured
PubMed files the paper under topics including Substance Withdrawal Syndrome, Buprenorphine, Magnesium Sulfate, Opioid-Related Disorders, Clonidine, Analgesics, Opioid and Iran.
The authors tagged it with the keywords Addiction and Drug.
What This Means in Plain Language
The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2024 (Journal of substance use and addiction treatment), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.